Literature DB >> 16900589

The inclusion of corticosteroids in treatment regimens for Kawasaki disease: effect on coronary aneurysms.

Luis R Espinoza1.   

Abstract

Entities:  

Year:  2006        PMID： 16900589     DOI： 10.1007/s11926-006-0011-9

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  10 in total

1.  Do we have a gold standard yet?

Authors:  Julien I E Hoffman
Journal:  J Am Coll Cardiol       Date:  2004-02-18       Impact factor: 24.094

Review 2.  Kawasaki disease.

Authors:  Fernanda Falcini
Journal:  Curr Opin Rheumatol       Date:  2006-01       Impact factor: 5.006

3.  Infliximab treatment for refractory Kawasaki syndrome.

Authors:  Jane C Burns; Wilbert H Mason; Sarmistha B Hauger; Hillel Janai; John F Bastian; Julie D Wohrley; Ian Balfour; Cynthia A Shen; Edward D Michel; Stanford T Shulman; Marian E Melish
Journal:  J Pediatr       Date:  2005-05       Impact factor: 4.406

4.  Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children.

Authors:  Yasunori Okada; Makoto Shinohara; Tomio Kobayashi; Yoshinari Inoue; Takeshi Tomomasa; Tohru Kobayashi; Akihiro Morikawa
Journal:  J Pediatr       Date:  2003-09       Impact factor: 4.406

5.  Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert
Journal:  Pediatrics       Date:  2004-12       Impact factor: 7.124

6.  Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.

Authors:  Robert P Sundel; Annette L Baker; David R Fulton; Jane W Newburger
Journal:  J Pediatr       Date:  2003-06       Impact factor: 4.406

7.  Kawasaki disease: effect of treatment on coronary artery involvement.

Authors:  H Kato; S Koike; T Yokoyama
Journal:  Pediatrics       Date:  1979-02       Impact factor: 7.124

8.  Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group.

Authors:  J C Burns; E V Capparelli; J A Brown; J W Newburger; M P Glode
Journal:  Pediatr Infect Dis J       Date:  1998-12       Impact factor: 2.129

9.  Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids.

Authors:  D A Wright; J W Newburger; A Baker; R P Sundel
Journal:  J Pediatr       Date:  1996-01       Impact factor: 4.406

10.  High-dose intravenous gammaglobulin for Kawasaki disease.

Authors:  K Furusho; T Kamiya; H Nakano; N Kiyosawa; K Shinomiya; T Hayashidera; T Tamura; O Hirose; Y Manabe; T Yokoyama
Journal:  Lancet       Date:  1984-11-10       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.